Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Sponsor: Guangdong Provincial People's Hospital
Listed as NCT01175096, this PHASE1/PHASE2 trial focuses on Carcinoid Tumor and Neuroendocrine Tumors and remains ongoing. Sponsored by Guangdong Provincial People's Hospital, it has been updated 6 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
-
Jun 2018 — Dec 2019 [monthly]
Unknown Status PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
Jul 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Guangdong Provincial People's Hospital
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Guangzhou, China